This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-2806v1 69/3/1150    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schild-Hay, L. J. Articles by Poirier, M. C. Search for Related Content PubMed PubMed Citation Articles by Schild-Hay, L. J. Articles by Poirier, M. C. Related Collections Preclinical Intervention Preclinical Intervention: In Vitro: Drugs, Mechanisms

Tamoxifen Induces Expression of Immune Response–Related Genes in Cultured Normal Human Mammary Epithelial Cells

¹ Carcinogen-DNA Interactions Section, LCBG, CCR, National Cancer Institute, NIH, Bethesda, Maryland; ² Division of Respiratory Disease Studies, National Institute for Occupational Safety and Health, CDC, Morgantown, West Virginia; ³ Bristol-Meyers Squibb, Discovery Medicine and Clinical Pharmacology, Pennington, New Jersey; and ⁴ PPD, Richmond, Virginia

Requests for reprints: Miriam C. Poirier, Carcinogen-DNA Interactions Section, CCR, LCBG, National Cancer Institute, NIH, Building 37 Room 4032, MSC-4255, 37 Convent Drive, Bethesda, MD 20892-4255. Phone: 301-402-1835; Fax: 301-402-8230; E-mail: poirierm{at}exchange.nih.gov.

Key Words: microarray • RT-PCR • TAM-DNA chemiluminescence immunoassay • IFN

Use of tamoxifen is associated with a 50% reduction in breast cancer incidence and an increase in endometrial cancer incidence. Here, we documented tamoxifen-induced gene expression changes in cultured normal human mammary epithelial cells (strains 5, 16, and 40), established from tissue taken at reduction mammoplasty from three individuals. Cells exposed to 0, 10, or 50 µmol/L of tamoxifen for 48 hours were evaluated for (E)--(deoxyguanosine-N²-yl)-tamoxifen (dG-N²-TAM) adduct formation using TAM-DNA (DNA modified with dG-N²-TAM) chemiluminescence immunoassay, gene expression changes using National Cancer Institute DNA-oligonucleotide microarray, and real-time PCR. At 48 hours, cells exposed to 10 and 50 µmol/L of tamoxifen were 85.6% and 48.4% viable, respectively, and there were no measurable dG-N²-TAM adducts. For microarrays, cells were exposed to 10 µmol/L of tamoxifen and genes with expression changes of >3-fold were as follows: 13 genes up-regulated and 1 down-regulated for strain 16; 17 genes up-regulated for strain 5, and 11 genes up-regulated for strain 40. Interferon-inducible genes (IFITM1, IFIT1, MXI, and GIP3), and a potassium ion channel (KCNJ1) were up-regulated in all three strains. No significant expression changes were found for genes related to estrogen or xenobiotic metabolism. Real-time PCR revealed the up-regulation of IFNA1 and confirmed the tamoxifen-induced up-regulation of the five other genes identified by microarray, with the exception of GIP3 and MX1, which were not up-regulated in strain 40. Induction of IFN-related genes in the three normal human mammary epithelial cell strains suggests that, in addition to hormonal effects, tamoxifen exposure may enhance immune response in normal breast tissue. [Cancer Res 2009;69(3):1150–5]